Cypherpunk Reports $77.2M Q1 Net Loss on ZEC Treasury Revaluation.
Key Takeaways
- Cypherpunk Technologies reported a net loss of $77.2 million attributable to common stockholders for the first quarter of 2026.
- The net loss was primarily driven by a $77.6 million unrealized loss on the fair value of its Zcash treasury holdings.
- As of March 31, 2026, cash and cash equivalents totaled $6.7 million, with digital assets receivable (ZEC treasury) valued at $73.8 million.
- The company expanded its ZEC treasury to 314,185.70 ZEC and purchased an additional 10,279.30 ZEC for $5.0 million between April 15 and May 13, 2026.
- A $5.0 million investment was made in Zcash Open Development Labs (ZODL).
- Subsidiary Leap Therapeutics received FDA Fast Track designation for sirexatamab in May 2026.
Cypherpunk Technologies recorded a net loss of $77.2 million attributable to common stockholders for the quarter ended March 31, 2026. This figure contrasts with a $15.4 million net loss reported in the same quarter of 2025. A significant factor in the Q1 2026 result was a $77.6 million unrealized loss recognized on the change in fair value of the company's ZEC treasury holdings.
The company’s financial position at the close of Q1 2026 showed cash and cash equivalents at $6.7 million, a reduction from $14.0 million at year-end 2025. Digital assets receivable, representing the ZEC treasury holdings, were valued at $73.8 million as of March 31, 2026. This valuation was based on a ZEC price of $240.47 on that specific date.
Get the Z-Brief
ZEC price analysis and the best Zcash content. 1-2x per month.
Operating expenses during the quarter included $0.2 million for research and development, a decrease from $12.9 million in Q1 2025. General and administrative expenses increased to $4.7 million for Q1 2026, up from $3.0 million in the prior year's first quarter.
Business Developments
Cypherpunk Technologies expanded its ZEC treasury during the reporting period, increasing its holdings to 314,185.70 ZEC. Furthermore, between April 15 and May 13, 2026, the company acquired an additional 10,279.30 ZEC for $5.0 million.
A strategic investment of $5.0 million was directed towards Zcash Open Development Labs (ZODL). This investment is intended to support ongoing Zcash protocol development efforts and the advancement of the Zodl wallet.
The company also launched a new corporate website and an investor dashboard at cypherpunk.com. This platform aims to provide enhanced visibility into the company's ZEC holdings and other key metrics for investors.
Through its subsidiary, Leap Therapeutics, significant progress was reported in its clinical programs. Sirexatamab received FDA Fast Track designation in May 2026 for its application in DKK1-high metastatic colorectal cancer. Leap Therapeutics additionally presented a new plasma DKK1 biomarker assay and reported significant Overall Response Rate (ORR) and Overall Survival (OS) benefits in DKK1-high patients at the AACR 2026 conference.